BVAXF (BioVaxys Technology) ROE % Adjusted to Book Value: 0.00% (As of Jul. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BioVaxys Technology ROE % Adjusted to Book Value?

BioVaxys Technology BVAXF ROE % Adjusted to Book Value is 0.00% as of Jul. 2025.

BioVaxys Technology's ROE % for the quarter that ended in Jul. 2025 was 0.00%. BioVaxys Technology's PB Ratio for the quarter that ended in Jul. 2025 was N/A. BioVaxys Technology's ROE % Adjusted to Book Value for the quarter that ended in Jul. 2025 was N/A.

BioVaxys Technology ROE % Adjusted to Book Value Related Terms

BioVaxys Technology ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for BioVaxys Technology's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVaxys Technology ROE % Adjusted to Book Value Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -7.53 -17.87 0.00 0.00 0.00

BioVaxys Technology Quarterly Data
Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BVAXF vs BPTH, AZTR, CLDI: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, BioVaxys Technology's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVaxys Technology ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's ROE % Adjusted to Book Value falls into.


BioVaxys Technology ROE % Adjusted to Book Value Calculation

BioVaxys Technology's ROE % Adjusted to Book Value for the fiscal year that ended in Oct. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

BioVaxys Technology's ROE % Adjusted to Book Value for the quarter that ended in Jul. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
BioVaxys Technology (BVAXF) has a ROE % Adjusted to Book Value of 0.00% as of Jul. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BioVaxys Technology and its competitors.
Is BioVaxys Technology's ROE % Adjusted to Book Value too high?
BioVaxys Technology's current ROE % Adjusted to Book Value is 0.00%.
How does BioVaxys Technology's ROE % Adjusted to Book Value compare to BPTH and AZTR?
BioVaxys Technology's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BioVaxys Technology and its competitors. BioVaxys Technology's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVaxys Technology stock overvalued right now?
BioVaxys Technology (BVAXF) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For BioVaxys Technology (BVAXF), the current ROE % Adjusted to Book Value is 0.00% as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVaxys Technology Business Description

Other Exchanges 5LB0:GermanyBIOV:Canada
Address 595 Howe Street, Suite 303, Vancouver, BC, CAN, V6C 2T5
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.